Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
November 07, 2023 08:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers...
Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer
October 23, 2023 08:30 ET
|
Qualigen Therapeutics, Inc.
Poster Includes Preclinical Data on Pan-RAS Compounds Demonstrating Inhibition in Breast Cancer Models CARLSBAD, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq:...
Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023
September 27, 2023 08:30 ET
|
Qualigen Therapeutics, Inc.
Two posters include data on potential clinical biomarkers and transcriptomic data associated with QN-302’s mechanism of action CARLSBAD, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Qualigen...
Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors
August 17, 2023 08:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers...
Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023
August 15, 2023 08:30 ET
|
Qualigen Therapeutics, Inc.
Investigational New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company Company divests FastPack® diagnostics business for approximately $5 million in all cash...
Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
August 01, 2023 08:30 ET
|
Qualigen Therapeutics, Inc.
Investigational New Drug (IND) clearance transitions Qualigen Therapeutics from preclinical to clinical-stage company and demonstrates leadership in G4-targeting therapies for areas of high unmet need...
Qualigen Therapeutics Divests FastPack® Diagnostics Business
July 24, 2023 08:15 ET
|
Qualigen Therapeutics, Inc.
All cash deal with Chembio Diagnostics, a US Subsidiary of the French Diagnostics Company BIOSYNEX, SA, solidifies Qualigen’s strategic priority on therapeutics CARLSBAD, Calif., July 24, 2023 ...
Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
June 05, 2023 08:15 ET
|
Qualigen Therapeutics, Inc.
Preclinical Data Show Potential to Overcome Resistance to Key KRAS-G12C Therapeutic Compounds CARLSBAD, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a...
Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023
May 16, 2023 08:00 ET
|
Qualigen Therapeutics, Inc.
Company Reports 123% Increase in Year-Over-Year Revenue CARLSBAD, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused...
Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
May 02, 2023 16:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN Qualigen Therapeutics, Inc.), a diversified life sciences company focused on developing treatments for...